(Total Views: 586)
Posted On: 11/03/2021 10:12:54 AM
Post# of 145876
Actually it's 75% of those who had reduced or low levels of CTCs that make up that 3600% number. 25% who had reduced or low levels of CTCs are not included in that number. My best guess is that most of the 25% were in extremely late stages of cancer and it may have been to late for leronlimab to turn them around.
Quote:
75% of the patients who exhibited a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival (“OS”) (p = 0.0004),
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)